| Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
| Management of aplastic anemia after failure of frontline immunosuppression |
|
Expert Review of Hematology |
Aplastic Anemia |
| Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
|
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
|
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
| Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes |
|
The New England Journal of Medicine |
Myelodysplastic Syndromes (MDS) |
| Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies |
|
Expert Opinion on Biological Therapy |
Myelodysplastic Syndromes (MDS) |
| Lowering the boom on lower-risk myelodysplastic syndromes |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
